Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Bytyqi, L.
Glycemic control with GlucoTab using insulin degludec in non-critically ill patients with type 2 diabetes at the general ward
Humanmedizin; [ Diplomarbeit ] Medical University of Graz; 2021. pp. 80
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Aberer Felix
- Mader Julia
- Altmetrics:
- Abstract:
- Introduction: Glycemic control is tightly linked to clinical outcomes in patients with diabetes. Using a clinical decision support system (GlucoTab®) improved glycemic control in previous studies, therefore we studied the effects of using GlucoTab® with a novel basal insulin analogue. (1–3) Objective: The aim of this clinical trial was to investigate and analyze the clinical efficacy, safety, and usability of GlucoTab® for glycemic control, specifically in combination with the ultralong-acting basal insulin degludec and the rapid-acting insulin aspart in hospitalized patients with diabetes mellitus type 2. Methods: GlucoTab® was used for diabetes management on 30 non-critically ill hospitalized patients at the Division of Endocrinology and Diabetology at the Department of Internal Medicine in Graz to investigate the efficacy of the system when used with insulin degludec. GlucoTab® uses an algorithm to support the management of patients with diabetes using insulin degludec (Tresiba®, an ultralong-acting basal insulin analogue) and insulin aspart (NovoRapid®, a rapid-acting insulin analogue). Blood glucose checks were performed pre-meal and at bedtime, as well as blinded continuous subcutaneous glucose monitoring (using the Abbott FreeStyle Libre Pro Flash Glucose Monitoring System) to better understand glycemic excursions over time. Results: The blood glucose target range of 70 – 140 mg/dl was achieved with 52.2 ± 10.2% (n=377) of blood glucose measurements falling into that range from a total of 722 measurements. The rate of hypoglycemia was low, with only 1.25% of blood glucose measurements at <70 mg/dl, 0.28% <54 mg/dl and no severe hypoglycemic event. The adherence to the GlucoTab® suggestions was high (93.6% adherence since study start) and the number of dose corrections was low, with -0.8 ±1.7 U for bolus insulin and 0.0 ± 0.2 U for basal insulin. Conclusion: Treatment support using the GlucoTab® system with Insulin Degludec in a hospital setting is safe and effective.